Son Mi Kyoung, Lim Nam-Kyoo, Kim Hyung Woo, Park Hyun-Young
Division of Cardiovascular and Rare Diseases, Center for Biomedical Science, Korea National Institute of Health, Chungcheongbuk-do, Republic of Korea.
PLoS One. 2017 Jun 21;12(6):e0179687. doi: 10.1371/journal.pone.0179687. eCollection 2017.
Atrial fibrillation (AF) is a major risk factor for ischemic stroke and associated with a 5-fold higher risk of stroke. In this retrospective cohort study, the incidence of and risk factors for ischemic stroke in patients with AF were identified. All patients (≥30 years old) without previous stroke who were diagnosed with AF in 2007-2013 were selected from the National Health Insurance Service-National Sample Cohort. To identify factors that influenced ischemic stroke risk, Cox proportional hazard regression analysis was conducted. During a mean follow-up duration of 3.2 years, 1022 (9.6%) patients were diagnosed with ischemic stroke. The overall incidence rate of ischemic stroke was 30.8/1000 person-years. Of all the ischemic stroke that occurred during the follow-up period, 61.0% occurred within 1-year after AF diagnosis. Of the patients with CHA2DS2-VASc score of ≥2, only 13.6% were receiving warfarin therapy within 30 days after AF diagnosis. Relative to no antithrombotic therapy, warfarin treatment for >90 days before the index event (ischemic stroke in stroke patients and death/study end in non-stroke patients) associated with decreased ischemic stroke risk (Hazard Ratio = 0.41, 95%confidence intervals = 0.32-0.53). Heart failure, hypertension, and diabetes mellitus associated with greater ischemic stroke risk. AF patients in Korea had a higher ischemic stroke incidence rate than patients in other countries and ischemic stroke commonly occurred at early phase after AF diagnosis. Long-term (>90 days) continuous warfarin treatment may be beneficial for AF patients. However, warfarin treatment rates were very low. To prevent stroke, programs that actively detect AF and provide anticoagulation therapy are needed.
心房颤动(AF)是缺血性卒中的主要危险因素,与卒中风险高出5倍相关。在这项回顾性队列研究中,确定了AF患者缺血性卒中的发病率及危险因素。从国民健康保险服务-全国样本队列中选取了2007年至2013年期间所有未发生过卒中且年龄≥30岁、被诊断为AF的患者。为了确定影响缺血性卒中风险的因素,进行了Cox比例风险回归分析。在平均3.2年的随访期内,1022例(9.6%)患者被诊断为缺血性卒中。缺血性卒中的总体发病率为30.8/1000人年。在随访期间发生的所有缺血性卒中中,61.0%发生在AF诊断后的1年内。CHA2DS2-VASc评分≥2的患者中,只有13.6%在AF诊断后30天内接受华法林治疗。相对于未进行抗栓治疗,在索引事件(卒中患者发生缺血性卒中,非卒中患者死亡/研究结束)前接受华法林治疗>90天与缺血性卒中风险降低相关(风险比=0.41,95%置信区间=0.32-0.53)。心力衰竭、高血压和糖尿病与更高的缺血性卒中风险相关。韩国的AF患者缺血性卒中发病率高于其他国家的患者,且缺血性卒中通常发生在AF诊断后的早期阶段。长期(>90天)持续华法林治疗可能对AF患者有益。然而,华法林治疗率非常低。为预防卒中,需要积极检测AF并提供抗凝治疗的项目。